Chongqing Qingyutang Pharmaceutical Co. Ltd.

Main purpose: This study uses Sulindac Tablets (Specification: 0.2 g) produced and owned by Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, Sulindac Tablets (Specification: 200 mg, trade name: Sulindac) owned by WATSON LABORATORIES INC is used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: Observe the safety of the test preparation Sulindac Tablets and the reference preparation Sulindac Tablets (Sulindac) in healthy subjects.

A single-center, randomized, open-label, single-dose, two-formulation, two-period crossover human bioequivalence study of cefditoren pivoxil tablets in healthy Chinese subjects.

This study investigated the pharmacokinetic characteristics of a single oral dose of Cefditoren Pivoxil Granules [test preparation, specification: 50 mg (potency)/0.5 g/bag] produced by Qingyutang Pharmaceutical Co., Ltd. of Fu'an Pharmaceutical Group or Cefditoren Pivoxil Granules [reference preparation, trade name: Mei Aike®, specification: 50 mg (potency)/0.5 g/bag] certified by Meiji Seika Pharma Co., Ltd. in healthy subjects under fasting and postprandial conditions, evaluated the bioequivalence and safety of the two preparations, and provided a basis for the registration application of the test preparation.